Möchten Sie immer auf dem neuesten Stand bleiben?

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medic

NEWPORT BEACH, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced that it has priced a...

Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc. Announces Encouraging Research Data Results Indicating Potential for Hair Restoration Using Proprietary

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondria

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai EnfinityTM

Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data

Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD